Pfizer, reportedly working with Goldman Sachs, is considering selling its hospital drugs unit while facing pressure from ...

Merck and AstraZeneca's MEK inhibitor Koselugo (selumetinib) showed significant improvement in adult neurofibromatosis type 1 ...

Merck KGaA's pimicotinib met its primary endpoint in Phase 3 MANEUVER trial for tenosynovial giant cell tumors, showing 54% ...

Diverge, a startup helping Medicaid members access care, raised $52 million led by Alphabet's GV. The company, launched in ...

No­var­tis will pay $150 mil­lion up­front to Schrödinger, in a pact an­nounced Tues­day to work to­geth­er on sev­er­al ...

GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...

AstraZeneca announces $2 billion investment to create 1,000 new US jobs, adding to previous $1.5 billion commitment. The $3.5 ...

Bayer CEO Bill Anderson affirmed plans to manage Xarelto's generic competition decline, as shares hit record low following Q3 ...

Apollo Therapeutics will pay $12M upfront and up to $926M in milestone payments to Sunshine Lake Pharma for worldwide rights (excluding China) to their FGF21/GLP-1 dual receptor agonist ...

Glucagon-like peptide-1 (GLP-1) receptor agonists have gained attention as potential treatments for a variety of ...

Thermo Fisher is closing a factory in Lexington, MA, and merging operations with a newer facility in Plainville, MA, to ...

Me is closing its therapeutics division and will wind down ongoing clinical trials, the struggling genetic testing company ...